

2nd Meeting of the Nutrition Support Working Group
16th Congress of Asia-Pacific Blood and Marrow Transplantation Group
Oct 31, 2011 (Sydney)

Proposal of Clinical Trial

Sung-Won Kim, M.D., Ph.D.

skim@ncc.go.jp

Department of Hematology and Stem Cell Transplantation
National Cancer Center Hospital
Tokyo, Japan

International randomized phase III study of glucose control

- After NST01 study, we have to plan a large scale phase III study of glucose control.
- In only Japan, patient recruitment is so hard.
- We would like to run the phase III study in Asia-Pacific countries/regions.

Hematologic diseases with the indication of alloH SCT
Organ function tolerable for full conditioning
18–60 years; PS 0 or 1

```
graph TD; A["Hematologic diseases with the indication of alloH SCT  
Organ function tolerable for full conditioning  
18–60 years; PS 0 or 1"] --> B["Randomized allocation of intensive glucose control  
or not  
disease risk, hospital, age, TBI or non-TBI"]; B --> C["Arm A: standard glucose control  
Glucose 80–180 mg/dL"]; B --> D["Arm B: intensive glucose control  
Glucose 80–110 mg/dL"];
```

**Randomized allocation of intensive glucose control
or not**
disease risk, hospital, age, TBI or non-TBI

Arm A: **standard glucose control**
Glucose 80–180 mg/dL

Arm B: **intensive glucose control**
Glucose 80–110 mg/dL